Last reviewed · How we verify
NCT05510934
Shared Care Thyroid Cancer Follow-up Utilizing Thyroid Cancer Assessment Reminder System (TCARS) Study - A Pilot Study.
trial testing Shared-care model in Low Risk Differentiated Thyroid Cancer in 60 participants. Currently enrolling.
30 September 2025
Quick facts
| Lead sponsor | Nova Scotia Health Authority |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 60 |
| Start date | 30 September 2022 |
| Primary completion | 30 September 2025 |
| Estimated completion | 30 December 2025 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Shared-care model
Conditions studied
- Low Risk Differentiated Thyroid Cancer — all drugs for Low Risk Differentiated Thyroid Cancer →
Sponsor
Nova Scotia Health Authority — full company profile →
Who can join
18 and older, any sex, with Low Risk Differentiated Thyroid Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to assess the feasibility of a shared-care model for low-risk differentiated thyroid cancer (DTC) patients, primary care practitioners (PCPs) and the tertiary care center utilizing a digital health-based thyroid cancer assessment reminder system (TCARS) in Medable with an expedited referral to specialists for rapid assessment in case of a concern of recurrence.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Decentralized Clinical Trials in Early Drug Development-A Framework Proposal.
Silva DJ, Nelson BE, Rodon J. · · 2024 · cited 2× · PMID 39219999 · DOI 10.36401/jipo-23-33
Verify or expand the search:
- PubMed search for NCT05510934
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Low Risk Differentiated Thyroid Cancer
Currently open trials in the same condition.
- NCT01837745 — Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients? · Phase 3 · active not recruiting
Other Nova Scotia Health Authority trials
Trials by the same sponsor.
- NCT03716999 — Starlight Therapy in Palliative Care · not yet recruiting
- NCT06987409 — Continuous Erector Spinae Block for Analgesia Following Lumbar Decompression · NA · not yet recruiting
- NCT06575621 — Knee-hip Surgery Wait-list Support Program · NA · not yet recruiting
- NCT07143162 — YOGA-FIT: Protocol for a Crossover Trial Investigating the Feasibility and Impact of Yoga for People With Stroke · NA · not yet recruiting
- NCT07239999 — Comparing Spinal Anesthesia With 1% Chloroprocaine Versus 1% Mepivacaine in Patients Undergoing Outpatient Primary Total · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05510934 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nova Scotia Health Authority
- Last refreshed: 21 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05510934.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing